News
-
Accoding to Teva, the FDA has approved the company’s QNASL beclomethasone dipropionate HFA nasal spray for the treatment of allergic rhinitis symptoms in children aged 4-11. The supplemental NDA for the pediatric product was accepted… Read more . . .
-
Verona Pharma has announced that Kenneth Newman, a former Acton Pharmaceuticals CMO and former Boehringer Ingelheim VP, Medical Affairs, will become Verona’s Chief Medical Officer as of January 1. At Acton, Newman headed up clinical… Read more . . .
-
Submit abstracts by January 10, 2015 at https://www.m-anage.com/Login.aspx?event=isam2015 More information available at http://www.isamcongress.com/index.php/site/index/14 Read more . . .
-
DDL 25 conference chair Gary Pitcairn opened the Silver Anniversary edition of Drug Delivery to the Lungs by welcoming approximately 550 attendees to the Edinburgh International Conference Centre. With the meeting’s rapid growth in attendance… Read more . . .
-
Novartis has reportedly sued Cipla in the Delhi High Court for infringing patents related to Novartis’s Onbrez Breezhaler indacaterol DPI (Arcapta Neohaler). Cipla began marketing a generic indacaterol DPI called “Unibrez” in October; after losing… Read more . . .
-
According to Insmed, the company has filed an MAA for its Arikayce liposomal amikacin for inhalation, and it has been informed by the EMA that the only remaining issue, a review of the Pediatric Investigation… Read more . . .
-
Hovione has announced that the FDA has found its Loures, Portugal manufacturing site to be GMP compliant, although the agency issued a Form 483 citing three inspectional observations. The inspection took place from December 1… Read more . . .
-
Submit poster abstracts by May 31, 2015. More information available at http://www.tefarco.it/TB2015/pages/posters.aspx# Read more . . .
-
Lightlake Therapeutics has agreed to license its intranasal naloxone for opioid overdose reversal to Adapt Pharma for possible development and sales milestones of more than $55 million, plus royalties, the company said. Lightlake recently announced… Read more . . .
-
GSK has announced that it will change the color of the Relvar Ellipta fluticasone/vilanterol DPI starting in January 2015. The company said that it will remove the color blue from the inhaler and its packaging… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA